FHND5071: a selective RET inhibitor with unique pharmacokinetic profile

被引：1
|
作者：
Zhu, Yongqiang
Wang, Jia
Shang, Minghong
机构：
来源：
CANCER RESEARCH | 2023年 / 83卷 / 08期
关键词：
D O I：
10.1158/1538-7445.AM2023-LB330
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
FHND5071
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Liposomal amphotericin B: a unique pharmacokinetic profile. An unfinished story.
    Azanza Perea, Jose Ramon
    Barberan, Jose
    REVISTA ESPANOLA DE QUIMIOTERAPIA, 2012, 25 (01) : 17 - 24
  • [32] Response to the Selective RET Inhibitor Selpercatinib (LOXO-292) in a Patient With RET Fusion-positive Atypical Lung Carcinoid
    Kander, Elizabeth M.
    Shah, Manisha H.
    Zhou, Ye
    Goyal, Ashima
    Palmer, Joshua D.
    Owen, Dwight H.
    Shilo, Konstantin
    Patel, Gopal
    Raval, Raju R.
    Gonzalez, Javier
    Nguyen, Michele
    Olek, Elizabeth
    Kherani, Jennifer
    Rothenberg, S. Michael
    Konda, Bhavana
    CLINICAL LUNG CANCER, 2021, 22 (03) : E442 - E445
  • [33] Pharmacokinetic profile of PBRM in rodents, a first selective covalent inhibitor of 17β-HSD1 for breast cancer and endometriosis treatments
    Maltais, Rene
    Trottier, Alexandre
    Roy, Jenny
    Ayan, Diana
    Bertrand, Nicolas
    Poirier, Donald
    JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY, 2018, 178 : 167 - 176
  • [34] Safety, Tolerability And Pharmacokinetic Profile Of Chf6001, A Novel Selective Inhaled Pde4 Inhibitor, In Healthy Volunteers
    Nandeuil, M. -A.
    Mariotti, F.
    Lucci, G.
    Santoro, D.
    Poli, G.
    Acerbi, D.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2016, 193
  • [35] A phase 1 study of LOXO-292, a potent and highly selective RET inhibitor, in patients with RET-altered cancers.
    Drilon, Alexander E.
    Subbiah, Vivek
    Oxnard, Geoffrey R.
    Bauer, Todd Michael
    Velcheti, Vamsidhar
    Lakhani, Nehal J.
    Besse, Benjamin
    Park, Keunchil
    Patel, Jyoti D.
    Cabanillas, Maria E.
    Johnson, Melissa Lynne
    Reckamp, Karen L.
    Boni, Valentina
    Loong, Herbert H. F.
    Schlumberger, Martin
    Solomon, Ben
    Cruickshank, Scott
    Rothenberg, Stephen M.
    Shah, Manisha H.
    Wirth, Lori J.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [36] Complete response to selpercatinib (LOXO-292), a highly selective RET inhibitor, in a patient with RET fusion-positive breast cancer
    Takeda, Masayuki
    Watanabe, Satomi
    Rothenberg, S. Michael
    Kherani, Jennifer
    French, Pearl P.
    Olek, Elizabeth
    CANCER RESEARCH, 2020, 80 (16)
  • [37] A phase I study of LOXO-292, a highly selective RET inhibitor, in pediatric patients with RET-altered cancers.
    DuBois, Steven G.
    Albert, Catherine Michelle
    Mascarenhas, Leo
    Laetsch, Theodore Willis
    van Tilburg, Cornelis Martinus
    Potter, Samara L.
    Turpin, Brian
    Bender, Julia Lynne Glade
    Spunt, Sheri L.
    Hladun, Raquel
    Casanova, Michela
    Ziegler, David Simon
    Morgenstern, Daniel A.
    Eary, Todd
    Ibabekci, Shannon
    Qamoos, Hope
    Rothenberg, Stephen M.
    Cox, Michael Craig
    Balis, Frank M.
    Pappo, Alberto S.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [38] Clinical Pharmacokinetic and Pharmacodynamic Overview of Nilotinib, a Selective Tyrosine Kinase Inhibitor
    Tian, Xianbin
    Zhang, Hefei
    Heimbach, Tycho
    He, Handan
    Buchbinder, Aby
    Aghoghovbia, Mary
    Hourcade-Potelleret, Florence
    JOURNAL OF CLINICAL PHARMACOLOGY, 2018, 58 (12): : 1533 - 1540
  • [39] Population Pharmacokinetic Analysis of Itacitinib, a Selective JAK-1 Inhibitor
    Barbour, April Marie
    Chen, Xuejun
    Yeleswaram, Swamy
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2019, 25 (03)
  • [40] Translational pharmacokinetic-pharmacodynamic modeling of a potent and selective MEK inhibitor
    Wong, Harvey
    Vernillet, Laurent
    Peterson, Amy
    Ware, Joseph A.
    Lee, Lillian
    Martini, Jean-Francois
    Yu, Peiwen
    Li, Connie
    Del Rosario, Geoffrey
    Prescott, John
    DRUG METABOLISM REVIEWS, 2009, 41 : 163 - 163
12345